

# Ana Galesic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11297341/publications.pdf>

Version: 2024-02-01

9  
papers

352  
citations

1307594

7  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

444  
citing authors

#	ARTICLE	IF	CITATIONS
1	Î±-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1511-1519.	7.1	156
2	O-GlcNAcylation of Î±-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding. ACS Chemical Biology, 2017, 12, 1020-1027.	3.4	81
3	O-GlcNAc modification inhibits the calpain-mediated cleavage of Î±-synuclein. Bioorganic and Medicinal Chemistry, 2017, 25, 4977-4982.	3.0	32
4	Synthesis of a Bis-thio-acetone (BTA) Analogue of the Lysine Isopeptide Bond and its Application to Investigate the Effects of Ubiquitination and SUMOylation on Î±-Synuclein Aggregation and Toxicity. ACS Chemical Biology, 2016, 11, 931-942.	3.4	27
5	Comparison of <i>N</i> -Acetyl-Glucosamine to Other Monosaccharides Reveals Structural Differences for the Inhibition of Î±-Synuclein Aggregation. ACS Chemical Biology, 2021, 16, 14-19.	3.4	22
6	Ubiquitination Can Change the Structure of the Î±-Synuclein Amyloid Fiber in a Site Selective Fashion. Journal of Organic Chemistry, 2020, 85, 1548-1555.	3.2	17
7	Design and Characterization of a Zn <sup>2+</sup> -Binding Four-Helix Bundle Protein in the Biophysical Chemistry Laboratory. Journal of Chemical Education, 2014, 91, 451-454.	2.3	8
8	Investigating the Effects of O-GlcNAc Modifications in Parkinsonâ€™s Disease Using Semisynthetic Î±-Synuclein. Methods in Molecular Biology, 2020, 2133, 313-326.	0.9	5
9	In Vivo Experimental and Analytical Studies for Bevacizumab Diffusion Coefficient Measurement in the Rabbit Vitreous Humor. Journal of Heat Transfer, 2021, 143, 032101.	2.1	4